APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy Induced Peripheral Neuropathy Treatment

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Selected research

Industry Growth & Trends

Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Growth and Trends Forecast to 2032

22 December 2025102 pages

Choose your research edition.

Industry ResearchChemotherapy Induced Peripheral Neuropathy Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.

Read the full market overview

The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.

Report Scope

This report provides a structured, data-driven view of the global Chemotherapy Induced Peripheral Neuropathy Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Chemotherapy Induced Peripheral Neuropathy Treatment market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Chemotherapy Induced Peripheral Neuropathy Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Chemotherapy Induced Peripheral Neuropathy Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Chemotherapy Induced Peripheral Neuropathy Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Company

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type

Calcium Channel α2-delta Ligands

Antidepressants

Opioids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Peripheral Neuropathy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Peripheral Neuropathy Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Calcium Channel α2-delta Ligands Table 2. Major Company of Antidepressants Table 3. Major Company of Opioids Table 4. Major Company of Others Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Type (2021-2026) Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (US$ Million) Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Type (2021-2026) Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2021-2026) & (US$/Unit) Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2027-2032) & (K Units) Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Type (2027-2032) Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2027-2032) & (US$ Million) Table 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Type (2027-2032) Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2027-2032) & (US$/Unit) Table 16. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 17. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 19. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 23. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (US$ Million) Table 26. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends Table 27. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Drivers Table 28. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Opportunities and Challenges Table 29. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Restraints Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2021-2026) Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2021-2026) & (K Units) Table 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Company (2021-2026) Table 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Major Company Production Sites and Headquarters Table 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Company, Product Type & Application Table 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021-2026) & (K Units) Table 43. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Region (2021-2026) Table 44. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021-2026) & (US$ Million) Table 45. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Region (2021-2026) Table 46. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2027-2032) & (K Units) Table 48. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Region (2027-2032) Table 49. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2027-2032) & (US$ Million) Table 50. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Region (2027-2032) Table 51. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 54. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Application (2021-2026) Table 55. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (US$ Million) Table 56. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Application (2021-2026) Table 57. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2021-2026) & (US$/Unit) Table 58. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2027-2032) & (K Units) Table 59. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Application (2027-2032) Table 60. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2027-2032) & (US$ Million) Table 61. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Application (2027-2032) Table 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2027-2032) & (US$/Unit) Table 63. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 64. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 66. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 70. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (US$ Million) Table 73. Aptinyx Inc Company Information Table 74. Aptinyx Inc Business Overview Table 75. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 77. Aptinyx Inc Recent Development Table 78. Asahi Kasei Pharma Corp Company Information Table 79. Asahi Kasei Pharma Corp Business Overview Table 80. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 82. Asahi Kasei Pharma Corp Recent Development Table 83. Regenacy Pharmaceuticals Company Information Table 84. Regenacy Pharmaceuticals Business Overview Table 85. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 87. Regenacy Pharmaceuticals Recent Development Table 88. MAKScientific LLC Company Information Table 89. MAKScientific LLC Business Overview Table 90. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 92. MAKScientific LLC Recent Development Table 93. Metys Pharmaceuticals AG Company Information Table 94. Metys Pharmaceuticals AG Business Overview Table 95. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 97. Metys Pharmaceuticals AG Recent Development Table 98. Nemus Bioscience Inc Company Information Table 99. Nemus Bioscience Inc Business Overview Table 100. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 102. Nemus Bioscience Inc Recent Development Table 103. PledPharma Company Information Table 104. PledPharma Business Overview Table 105. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 107. PledPharma Recent Development Table 108. Sova Pharmaceuticals Inc Company Information Table 109. Sova Pharmaceuticals Inc Business Overview Table 110. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 112. Sova Pharmaceuticals Inc Recent Development Table 113. DermaXon LLC Company Information Table 114. DermaXon LLC Business Overview Table 115. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 117. DermaXon LLC Recent Development Table 118. Kineta Inc Company Information Table 119. Kineta Inc Business Overview Table 120. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 122. Kineta Inc Recent Development Table 123. Krenitsky Pharmaceuticals Inc Company Information Table 124. Krenitsky Pharmaceuticals Inc Business Overview Table 125. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 127. Krenitsky Pharmaceuticals Inc Recent Development Table 128. PeriphaGen Company Information Table 129. PeriphaGen Business Overview Table 130. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 132. PeriphaGen Recent Development Table 133. Apexian Pharma Company Information Table 134. Apexian Pharma Business Overview Table 135. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 137. Apexian Pharma Recent Development Table 138. WinSanTor Company Information Table 139. WinSanTor Business Overview Table 140. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 142. WinSanTor Recent Development Table 143. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 144. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 145. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2026) Table 146. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032) & (K Units) Table 147. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Country (2027-2032) Table 148. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country (2021-2026) Table 151. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Country (2027-2032) Table 153. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 154. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 155. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2026) Table 156. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032) & (K Units) Table 157. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Country (2027-2032) Table 158. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026) & (US$ Million) Table 160. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country (2021-2026) Table 161. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Country (2027-2032) Table 163. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 164. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 165. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2026) Table 166. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032) & (K Units) Table 167. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026) & (US$ Million) Table 170. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country (2021-2026) Table 171. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Country (2027-2032) Table 173. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 174. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 175. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2026) Table 176. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032) & (K Units) Table 177. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Country (2027-2032) Table 178. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026) & (US$ Million) Table 180. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country (2021-2026) Table 181. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Country (2027-2032) Table 183. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 184. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 185. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2026) Table 186. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032) & (K Units) Table 187. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Country (2027-2032) Table 188. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026) & (US$ Million) Table 190. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country (2021-2026) Table 191. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Country (2027-2032) Table 193. Key Raw Materials Table 194. Raw Materials Key Suppliers Table 195. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List Table 196. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List Table 197. Research Programs/Design for This Report Table 198. Authors List of This Report Table 199. Secondary Sources Table 200. Primary Sources List of Figures Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Image Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (2021-2032) & (K Units) Figure 5. Calcium Channel α2-delta Ligands Image Figure 6. Global Calcium Channel α2-delta Ligands Sales YoY Growth (2021-2032) & (K Units) Figure 7. Antidepressants Image Figure 8. Global Antidepressants Sales YoY Growth (2021-2032) & (K Units) Figure 9. Opioids Image Figure 10. Global Opioids Sales YoY Growth (2021-2032) & (K Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type 2025 VS 2032 Figure 15. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Type in 2025 Figure 16. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Type in 2025 Figure 17. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Type in 2025 Figure 18. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Type in 2025 Figure 21. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Platinum Agents Image Figure 28. Global Platinum Agents Sales YoY Growth (2021-2032) & (K Units) Figure 29. Taxanes Image Figure 30. Global Taxanes Sales YoY Growth (2021-2032) & (K Units) Figure 31. Vinca Alkaloids Image Figure 32. Global Vinca Alkaloids Sales YoY Growth (2021-2032) & (K Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application 2025 VS 2032 Figure 37. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Application in 2025 Figure 38. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Application in 2025 Figure 39. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Application in 2025 Figure 40. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Application in 2025 Figure 43. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Application in 2025 Figure 47. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Chemotherapy Induced Peripheral Neuropathy Treatment Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Calcium Channel α2-delta Ligands
  • Antidepressants
  • Opioids
  • Others
Applications
  • Platinum Agents
  • Taxanes
  • Vinca Alkaloids
  • Others
Companies covered
  • Aptinyx Inc
  • Asahi Kasei Pharma Corp
  • Regenacy Pharmaceuticals
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Nemus Bioscience Inc
  • PledPharma
  • Sova Pharmaceuticals Inc
  • DermaXon LLC
  • Kineta Inc
  • Krenitsky Pharmaceuticals Inc
  • PeriphaGen
  • Apexian Pharma
  • WinSanTor

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Type
  6. 1.3.1 Calcium Channel α2-delta Ligands
  7. 1.3.2 Antidepressants
  8. 1.3.3 Opioids
  9. 1.3.4 Others
  10. 1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
  11. 1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
  2. 2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Drivers
  3. 2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Opportunities and Challenges
  4. 2.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2026)
  2. 3.2 Global Top Players by Chemotherapy Induced Peripheral Neuropathy Treatment Sales (2021-2026)
  3. 3.3 Global Top Players by Chemotherapy Induced Peripheral Neuropathy Treatment Price (2021-2026)
  4. 3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Major Company Production Sites & Headquarters
  6. 3.6 Global Chemotherapy Induced Peripheral Neuropathy Treatment Company, Product Type & Application
  7. 3.7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chemotherapy Induced Peripheral Neuropathy Treatment Tier 1, Tier 2, and Tier 3
4 Chemotherapy Induced Peripheral Neuropathy Treatment Regional Status and Outlook
  1. 4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Region
  3. 4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Region
  7. 4.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Chemotherapy Induced Peripheral Neuropathy Treatment by Application
  1. 5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Application
  2. 5.1.1 Platinum Agents
  3. 5.1.2 Taxanes
  4. 5.1.3 Vinca Alkaloids
  5. 5.1.4 Others
  6. 5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
  7. 5.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Aptinyx Inc
  2. 6.1.1 Aptinyx Inc Company Information
  3. 6.1.2 Aptinyx Inc Business Overview
  4. 6.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  6. 6.1.5 Aptinyx Inc Recent Developments
  7. 6.2 Asahi Kasei Pharma Corp
  8. 6.2.1 Asahi Kasei Pharma Corp Company Information
  9. 6.2.2 Asahi Kasei Pharma Corp Business Overview
  10. 6.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  12. 6.2.5 Asahi Kasei Pharma Corp Recent Developments
  13. 6.3 Regenacy Pharmaceuticals
  14. 6.3.1 Regenacy Pharmaceuticals Company Information
  15. 6.3.2 Regenacy Pharmaceuticals Business Overview
  16. 6.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  18. 6.3.5 Regenacy Pharmaceuticals Recent Developments
  19. 6.4 MAKScientific LLC
  20. 6.4.1 MAKScientific LLC Company Information
  21. 6.4.2 MAKScientific LLC Business Overview
  22. 6.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  24. 6.4.5 MAKScientific LLC Recent Developments
  25. 6.5 Metys Pharmaceuticals AG
  26. 6.5.1 Metys Pharmaceuticals AG Company Information
  27. 6.5.2 Metys Pharmaceuticals AG Business Overview
  28. 6.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  30. 6.5.5 Metys Pharmaceuticals AG Recent Developments
  31. 6.6 Nemus Bioscience Inc
  32. 6.6.1 Nemus Bioscience Inc Company Information
  33. 6.6.2 Nemus Bioscience Inc Business Overview
  34. 6.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  36. 6.6.5 Nemus Bioscience Inc Recent Developments
  37. 6.7 PledPharma
  38. 6.7.1 PledPharma Company Information
  39. 6.7.2 PledPharma Business Overview
  40. 6.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  42. 6.7.5 PledPharma Recent Developments
  43. 6.8 Sova Pharmaceuticals Inc
  44. 6.8.1 Sova Pharmaceuticals Inc Company Information
  45. 6.8.2 Sova Pharmaceuticals Inc Business Overview
  46. 6.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  48. 6.8.5 Sova Pharmaceuticals Inc Recent Developments
  49. 6.9 DermaXon LLC
  50. 6.9.1 DermaXon LLC Company Information
  51. 6.9.2 DermaXon LLC Business Overview
  52. 6.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  54. 6.9.5 DermaXon LLC Recent Developments
  55. 6.10 Kineta Inc
  56. 6.10.1 Kineta Inc Company Information
  57. 6.10.2 Kineta Inc Business Overview
  58. 6.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  60. 6.10.5 Kineta Inc Recent Developments
  61. 6.11 Krenitsky Pharmaceuticals Inc
  62. 6.11.1 Krenitsky Pharmaceuticals Inc Company Information
  63. 6.11.2 Krenitsky Pharmaceuticals Inc Business Overview
  64. 6.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  66. 6.11.5 Krenitsky Pharmaceuticals Inc Recent Developments
  67. 6.12 PeriphaGen
  68. 6.12.1 PeriphaGen Company Information
  69. 6.12.2 PeriphaGen Business Overview
  70. 6.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  72. 6.12.5 PeriphaGen Recent Developments
  73. 6.13 Apexian Pharma
  74. 6.13.1 Apexian Pharma Company Information
  75. 6.13.2 Apexian Pharma Business Overview
  76. 6.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  78. 6.13.5 Apexian Pharma Recent Developments
  79. 6.14 WinSanTor
  80. 6.14.1 WinSanTor Company Information
  81. 6.14.2 WinSanTor Business Overview
  82. 6.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  84. 6.14.5 WinSanTor Recent Developments
7 North America by Country
  1. 7.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
  2. 7.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026)
  4. 7.1.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032)
  5. 7.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
  6. 7.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026)
  8. 7.2.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
  2. 8.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026)
  4. 8.1.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
  6. 8.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026)
  8. 8.2.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
  2. 9.1.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
  6. 9.2.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
  2. 10.1.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026)
  4. 10.1.3 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032)
  5. 10.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
  6. 10.2.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026)
  8. 10.2.3 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
  2. 11.1.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
  6. 11.2.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain Analysis
  2. 12.1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Chemotherapy Induced Peripheral Neuropathy Treatment Production Mode & Process
  7. 12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors
  10. 12.2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst